NCT05482074 2024-01-19
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
Dana-Farber Cancer Institute
Phase 2 Withdrawn
Clinical Trials
9 trialsNCT05677373 2023-08-18
Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma
Alliance for Clinical Trials in Oncology
Phase 1/2 Withdrawn
NCT01930968 2022-02-23
Definity for Ultrasound of Intraocular Tumors
Emory University
Withdrawn
NCT04184518 2020-06-02
CEDUVEAL-M
Grupo Español Multidisciplinar de Melanoma
Phase 2 Withdrawn
NCT03022565 2020-02-06
Vorinostat in Patients With Class 2 High Risk Uveal Melanoma
University of Miami
Phase EARLY_PHASE1 Withdrawn
NCT03326258 2018-07-18
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT00406120 2018-06-26
Validation of a Molecular Prognostic Test for Eye Melanoma
Washington University School of Medicine
Withdrawn
NCT01328106 2017-12-12
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
GlaxoSmithKline
Phase 2 Withdrawn
NCT00621439 2013-12-02
Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye
Emory University
Phase NA Withdrawn